Lamotrigine (All indications)

Very preterm (28 to 32 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12611
R47527		 Van Marter (Lamotrigine) (Controls unexposed, disease free), 2021 Prematurity - Moderate (28-33 wk gestational age) at least 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 0.96 [0.06;15.60] C
excluded (control group) 		1/110   1/106 2 110
ref
S12613
R47539		 Van Marter (Lamotrigine) (Controls unexposed, sick), 2021 Prematurity - Moderate (28-33 wk gestational age) at least 1st trimester prospective cohort unexposed, sick Adjustment: No 0.13 [0.01;2.17] C 1/110   1/15 2 110
ref
S8978
R30428		 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Gestational age at birth (27–31 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.64 [0.33;1.23] C 9/2,813   8,556/1,707,707 8,565 2,813
ref
Total 2 studies 0.53 [0.19;1.45] 8,567 2,923
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Van Marter (Lamotrigine) (Controls unexposed, sick), 2021Van Marter, 2021 1 0.13[0.01; 2.17]211012%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: low Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Coste, 2020 2 0.64[0.33; 1.23]8,5652,81388%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 15% 0.53[0.19; 1.45]8,5672,9230.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Controls unexposed, sick; 2: Lamotrigine) (Controls unexposed NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.53[0.19; 1.45]8,5672,92315%NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.64[0.33; 1.23]8,5652,813 -NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 0.13[0.01; 2.17]2110 -NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 1 Tags Adjustment   - No  - No 0.53[0.19; 1.45]8,5672,92315%NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 All studiesAll studies 0.53[0.19; 1.45]8,5672,92315%NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12611

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.65[0.34; 1.23]8,5672,9230%NAVan Marter (Lamotrigine) (Controls unexposed, disease free), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 unexposed, sick controlsunexposed, sick controls Out of scale0.13[0.01; 2.17]2110 -NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 10.510.01.0